Selected Presentations & Appearances
Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy.
- 2018 Annual Conference
· November 7, 2018
Invited Talk
Society for Immunotherapy of Cancer,
Washington, DC
Tumor-mediated Modulation of Immunometabolism as a Mechanism of Immunotherapy Resistance.
- Immuno-Oncology Summit
· August 27, 2018
- August 27, 2018
Invited Talk
CHI,
Boston, MA
Investigating the Role of Innate Immunity in Adaptive Resistance to Cancer Immunotherapy
- Biomarkers and Immuno-Oncology World Congress
· June 13, 2018
- June 13, 2018
Invited Talk
CHI,
Boston, MA
Role of the Wnt-β-catenin Signaling Pathway in Tumor-mediated Immune Evasion and Immunotherapy Resistance
· March 27, 2018
- March 29, 2018
Invited Talk
Duke-NUS,
Singapore
Uncovering the Role of the Wnt-β-catenin Signaling Pathway in Driving Melanoma Immune Evasion and Immunotherapy Resistance
- 2018 Duke Solid Tumor Therapeutics Program Annual Retreat.
· March 19, 2018
- March 19, 2018
Invited Talk
Duke University,
Durham, NC
Uncovering the Role of the Wnt-β-catenin Signaling Pathway in Driving Melanoma Immune Evasion and Immunotherapy Resistance
- 2018 Pinnel Center Talk
· March 2, 2018
- March 2, 2018
Invited Talk
Duke University,
Durham, NC
The Immune System and Cancer: Mechanisms of Immune Suppression
- ASCO-SITC Lecture
· June 1, 2017
- June 2, 2017
Invited Talk
ASCO ,
McCormick Place, Chicago, IL
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.
- Society for Immunotherapy of Cancer 2016 Annual Meeting
· November 11, 2016
- November 13, 2016
Invited Talk
Society for Immunotherapy of Cancer (SITC),
Washington, DC
Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma.
- 2nd Annual Summit on Melanoma
· September 18, 2015
- September 20, 2015
Invited Talk
DAVA Oncology,
The Langham Hotel, Pasadena, CA
Basic Mechanisms of Tumor Immune Suppression
- SITC Regional Advances in Cancer Immunotherapy
· May 29, 2015
- May 29, 2015
Lecture
Society for Immunotherapy of Cancer,
McCormick Place, Chicago, IL
Modulating the Immune Response.
- SITC Regional Advances in Cancer Immunotherapy
· October 3, 2014
- October 4, 2015
Lecture
Society for Immunotherapy of Cancer,
Charlotte, NC
Exploring Dendritic Cell-Targeted Immune Evasion Mechanisms in Melanoma: Developing Pharmacological Strategies to Synergistically Enhance Immunotherapy Efficacy
· August 22, 2014
- August 23, 2014
Invited Talk
Georgia Regents University,
Georgia Regents University, Augusta, GA
Service to the Profession
Manuscript Reviewer
- Journal of Clinical Investigation
·
January 1, 2014
- November 1, 2015
Editorial Activities
Manuscript Reviewer
- Frontiers in Immunology
·
2014
Editorial Activities
Manuscript Reviewer
- Cancer Immunology Immunotherapy
·
2014
Editorial Activities
Manuscript Reviewer
- Plos One
·
January 1, 2013
- November 24, 2015
Editorial Activities
Service to Duke
Pharmacology and Cancer Biology Chair Search Committee
(Department)
·
2021
- 2022
Committee Service
·
2017
Committee Service
Duke University
Clinical Activities
Manage patients with advanced skin cancers including melanoma, Merkel cell carcinoma, squamous cell carcinoma, and basal cell carcinoma. One full clinic day weekly. In-patient advanced skin cancer consults.